|
|
Post by lakers on Nov 11, 2016 17:25:48 GMT -5
stocktwits.com/NatesNotesNatesNotes @longtermliability at this stage of the game, it would certainly appear that there must have been some reason for China to have come up in Nov. 10 at 6:12 PM NatesNotes @longtermliability the course of discussing $MNKD insulin needs vs. cash needs with Amphastar; now that relationship w/ Sanofi is fully Nov. 10 at 6:13 PM NatesNotes @longtermliability severed, it should, in theory anyway, allow other cos to feel more comfortable entering into talks (of any sort) w/ $MNKD
Nov. 10 at 6:14 PM NatesNotes @longtermliability (and the fact that $MNKD was willing to take less from Sanofi than some felt they could have held on for certainly does Nov. 10 at 6:16 PM NatesNotes Nate Pile @longtermliability lend itself to the idea that there could be some sort of deal coming "sooner rather than later"... but who knows :-) ) With respect to our insulin API business, we continue to have discussions with MannKind regarding delaying their minimum commitments under the supply agreement due to their cash flow issues. We believe that we're close to an agreement on this issue. Additionally, we have previously disclosed a commitment to invest an additional $12 million in our business in Nanjing, China. We plan to complete this estimate by the end of the year. Amphastar Pharmaceuticals' (AMPH) on Q3 2016 Results - Earnings Call Transcript $AMPH www.seekingalpha.com/article/4021356On November 9, 2016, the Company entered into an amendment (the “Amendment”) to the Supply Agreement (the “Amphastar Agreement”), dated July 31, 2014, by and between the Company and Amphastar Pharmaceuticals, Inc. (“Amphastar”). Pursuant to the Amendment, the term of the Amphastar Agreement was extended from December 1, 2019 to December 31, 2023. In addition, the delivery schedule was modified to provide that Amphastar will ship €2.7 million of insulin to the Company in the fourth quarter of 2017, €8.9 million in 2018, €11.6 million in 2019, €15.5 million in 2020 and in 2021, and €19.4 million in 2022 and in 2023. The Company also granted Amphastar a right of first refusal to participate in the development and commercialization of Afrezza in China through a potential business collaboration.On November 9, 2016, the Company entered into an amendment to the Insulin Purchase Option Agreement, dated January 1, 2015, by and between the Company and Amphastar, pursuant to which the aggregate cancellation fees that the Company will incur in the event that such additional insulin is not purchased were lowered from $5.3 million for the period October 1, 2016 through 2018 to $3.4 million over the same period. investors.mannkindcorp.com/secfiling.cfm?filingID=1193125-16-764506&CIK=899460One of the most frequently asked questions they are coming through on online we has to do with delisting. I am not sure what exactly to say about that. I am not terribly concerned about delisting, I think the news today we're long way to solving that problem, it's not going to be an issue till sometime in like the second quarter of next year by which point we have, we expect to have a lot of things accomplish that will make this whole issue go away.seekingalpha.com/article/4021887-mannkinds-mnkd-ceo-matthew-pfeffer-q3-2016-results-earnings-call-transcript?part=single
|
|
|
|
Post by peppy on Nov 11, 2016 17:34:03 GMT -5
Just talking here. Do you remember the conference call about a year ago, Hakan was on it, when gs and jpm were still covering MNKD,
In the question and answer period an individual from china said he wanted to invest in MNKD and had resources.
the exchange a bit difficult in that moment. Sanofi still involved?
Do you remember?
Any connection?
|
|
|
|
Post by lakers on Nov 11, 2016 18:10:07 GMT -5
Chinese Market Offers New Life to Many Drugs By finding local partners in China, global drugmakers have chance to make money on drugs that have fallen short elsewhere www.wsj.com/articles/chinese-market-offers-new-life-to-many-drugs-1459279444SHANGHAI—Drugs that failed to make it to the market in the U.S. and elsewhere are finding new life in China. In 2013, Bristol-Myers Squibb Co. stopped global trials of a first-line liver-cancer drug after it failed to outperform a rival. Instead, the company licensed the drug, brivanib, to a Chinese startup. The startup, Shanghai-based Zai Lab Ltd., sees high potential for brivanib in China because its rival—sorafenib, developed by Bayer AG and Onyx Pharmaceuticals Inc.—costs around $7,500 for one month of treatment and isn’t covered by national insurance. “We hope to give the Chinese patients a more reasonable price,” said Samantha Du, founder of Zai Lab, one of several Chinese firms joining forces with Western pharmaceuticals over partially developed drugs in China. They’re chasing a market where the best new global drugs face long delays while regulators clear a speedier path for Chinese medications. But the new trend also raises the question of whether China has become a dumping ground for inferior drugs. I. Glenn Cohen, a Harvard Law School professor who studies medical ethics, said that because of differences in regulatory standards it isn’t unusual or unlawful for a company to get a drug approved in one jurisdiction and not another. For one thing, in China a drug doesn’t have to prove superiority over existing drugs—a major hurdle in the U.S., where 90% of candidates get dropped in the clinical-trial process.
The stroke drug cinepazide was withdrawn from Spain, Italy and France in the late 1980s and 1990s, after reports of blood disorders associated with its use. By 2010, it had become China’s top-selling drug, according to Credit Suisse Equity Research. The company that markets it, Sihuan Pharmaceutical Holdings Group Ltd., says the generic cinepazide it produces is more purified than the branded version that was sold in Europe, and its safety and efficacy is recognized by Chinese authorities and patients. By finding local partners in China, global drugmakers have a second chance to make money on drugs that have fallen short elsewhere. Beijing, which wants to build a competitive domestic pharmaceutical market, welcomes such partnerships.
For Chinese consumers, the trend could mean shorter wait times and lower costs for new drugs—even if they aren’t the best in their class. For now, Chinese regulators ask for additional testing of drugs approved by the U.S. FDA. Approval to start trials can take more than a year. By comparison, the U.S. regulator says clinical trials can start 30 days after an application has been submitted.
Only 21% of drugs launched globally between 2008 and 2012 were available in China as of 2013, compared with 68% in the U.S., according to market researcher IMS Health. |
|
|
|
Post by letitride on Nov 11, 2016 18:21:47 GMT -5
Just talking here. Do you remember the conference call about a year ago, Hakan was on it, when gs and jpm were still covering MNKD, In the question and answer period an individual from china said he wanted to invest in MNKD and had resources. the exchange a bit difficult in that moment. Sanofi still involved? Do you remember? Any connection? It seems like I do remember a China man wanting to make a big investment in Mannkind a cc or two ago . that's like things that make you go hmmmmmmmmmmmmmm |
|
|
|
Post by sweedee79 on Nov 11, 2016 18:24:50 GMT -5
Just talking here. Do you remember the conference call about a year ago, Hakan was on it, when gs and jpm were still covering MNKD, In the question and answer period an individual from china said he wanted to invest in MNKD and had resources. the exchange a bit difficult in that moment. Sanofi still involved? Do you remember? Any connection? I remember the guy at the last annual shareholder meeting ..... |
|
|
|
Post by sayhey24 on Nov 11, 2016 19:24:57 GMT -5
Just talking here. Do you remember the conference call about a year ago, Hakan was on it, when gs and jpm were still covering MNKD, In the question and answer period an individual from china said he wanted to invest in MNKD and had resources. the exchange a bit difficult in that moment. Sanofi still involved? Do you remember? Any connection? I remember the guy at the last annual shareholder meeting ..... That guy was about 10 feet from me at the ASM. He is not associated with Amphastar. Amphastar has been after Mannkind for some time. MNKD may be better served doing a deal with San Meditech or others and just giving whoever a marketing and distribution agreement. The good news with Amphastar was MNKD was not so desperate where they needed to do the deal when it seemed like Amphastar had them over a barrel. Given that and the fact that Mike is very upbeat and put his own money in and Matt seems to have ZERO concerns about money, gives me great hope. I am still waiting on the $200M PO from Al's tiny country, hope springs eternal. |
|
|
|
Post by Chris-C on Nov 11, 2016 19:27:00 GMT -5
@sweedie79
I was thinking the same thing. I think it is a virtual certainty that there was a follow up discussion with "Al's friend" representing the "group of investors". Annual public meetings are not the place to do deals or fuel speculation, but I wonder if anyone present noticed a post meeting discussion and exchange of business cards between any board members and the gentleman in question?
|
|
|
|
Post by sportsrancho on Nov 11, 2016 19:33:40 GMT -5
He was turned down. Twice
|
|
|
|
Post by snowballsmommy on Nov 11, 2016 19:37:21 GMT -5
@sweedie79 I was thinking the same thing. I think it is a virtual certainty that there was a follow up discussion with "Al's friend" representing the "group of investors". Annual public meetings are not the place to do deals or fuel speculation, but I wonder if anyone present noticed a post meeting discussion and exchange of business cards between any board members and the gentleman in question? He absolutely walked into private quarters with the Board members! |
|
|
|
Post by falconquest on Nov 11, 2016 19:39:35 GMT -5
Oh for cripes sake, there has been speculation surrounding Mannkind for years. You want to know why I first invested in this company? Because I received a tip that this this start-up company was looking to partner a new diabetes drug. That was at $19.00 per share and here we are 10 years+ later still speculating on potential deals. We should be discussing whether guidance is too low or too high this quarter based on sales projections. It's about selling the product not the company!
|
|
|
|
Post by brotherm1 on Nov 11, 2016 19:45:05 GMT -5
Henry Orlosky. A very recent conversation with a prominent MNKD shareholder told me Mr. Orlosky no longer has interest at the present time as he moved on to other investment(s). From what I was told he was offended by MNKD management and moved on. I was told he had offered $500m cash for 51% of MNKD and the 51% would have enabled his current business to write off the $2-3 million MNKD loss. He allegedly needed the majority of shares for the tax write off and not for management purposes as I was told he did not plan on changing management. He allegedly also put the offer in writing to MNKD in February before the shareholder meeting where he verbalized it. Another very recent measage I recieved from another investor via Mr. Orlosky was that he owns 836,000 shares if MNKD and thus another reason he wants MNKD to succeed. Whether or not he will enter the picture again in the future remains to be seen. Good news to me Sayhey that Amphastar has been interested. Thanks
|
|
|
|
Post by brotherm1 on Nov 11, 2016 19:49:28 GMT -5
Oh for cripes sake, there has been speculation surrounding Mannkind for years. You want to know why I first invested in this company? Because I received a tip that this this start-up company was looking to partner a new diabetes drug. That was at $19.00 per share and here we are 10 years+ later still speculating on potential deals. We should be discussing whether guidance is too low or too high this quarter based on sales projections. It's about selling the product not the company! Do I want to know why you first invested in this company? No, I really don't care. I find it good to hear about others that are interested in a stake in MNKD It's a positive thing |
|
|
|
Post by falconquest on Nov 11, 2016 20:02:49 GMT -5
Oh for cripes sake, there has been speculation surrounding Mannkind for years. You want to know why I first invested in this company? Because I received a tip that this this start-up company was looking to partner a new diabetes drug. That was at $19.00 per share and here we are 10 years+ later still speculating on potential deals. We should be discussing whether guidance is too low or too high this quarter based on sales projections. It's about selling the product not the company! Do I want to know why you first invested in this company? No, I really don't care. I find it good to hear about others that are interested in a stake in MNKD It's a positive thing My point in sharing is to put the comments in perspective. There has been speculation surrounding Mannkind for years. I get being positive and based on the recent conference call investors have a right to feel positive. However, it is hard to be positive and listen to these comments when you're down over $200K. It pains me just to write that. Now, I think Matt and Mike and Ray are doing a great job but for once the issue has to be about sales and not speculation of a buy-out. Do I care what you think of my comments..........not so much! |
|
|
|
Post by brotherm1 on Nov 11, 2016 20:12:49 GMT -5
I believe there are threads about sales? If not you can start one. This thread was about interest in China
|
|
|
|
Post by falconquest on Nov 11, 2016 20:30:32 GMT -5
I believe there are threads about sales? If not you can start one. This thread was about interest in China Understood, but I was responding to a direct challenge to my comments. It was not my intention to deviate from the original posters comments but merely to make a point about a direct challenge to my thoughts. When you have been here for as long as I have and been through as much as I have then in my mind one "earns" a certain right to...............discourse. If you don't agree then.......I just don't care. |
|
